Recombinant Human BRD2 His Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-51885
Key Product Details
Source
E. coli
Tag
His
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
A recombinant protein with a N-Terminal His-tag and corresponding to the amino acids 1-455 of Human BRD2
Source: E.coli
Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGSMLQNVTP HNKLPGEGNA GLLGLGPEAA APGKRIRKPS LLYEGFESPT MASVPALQLT PANPPPPEVS NPKKPGRVTN QLQYLHKVVM KALWKHQFAW PFRQPVDAVK LGLPDYHKII KQPMDMGTIK RRLENNYYWA ASECMQDFNT MFTNCYIYNK PTDDIVLMAQ TLEKIFLQKV ASMPQEEQEL VVTIPKNSHK KGAKLAALQG SVTSAHQVPA VSSVSHTALY TPPPEIPTTV LNIPHPSVIS SPLLKSLHSA GPPLLAVTAA PPAQPLAKKK GVKRKADTTT PTPTAILAPG SPASPPGSLE PKAARLPPMR RESGRPIKPP RKDLPDSQQQ HQSSKKGKLS EQLKHCNGIL KELLSKKHAA YAWPFYKPVD ASALGLHDYH DIIKHPMDLS TVKRKMENRD YRDAQEFAAD VRLMFSNCYK YNPPDHDVVA MARKLQDVFE FRYAKMPD
Purity
>90%, by SDS-PAGE
Predicted Molecular Mass
52.8 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Protein / Peptide Type
Recombinant Protein
Scientific Data Images for Recombinant Human BRD2 His Protein
![SDS-PAGE: Recombinant Human BRD2 His Protein [NBP2-51885]](https://resources.bio-techne.com/images/products/BRD2-Recombinant-Protein-SDS-Page-NBP2-51885-img0001.jpg "SDS-PAGE: Recombinant Human BRD2 His Protein [NBP2-51885]")
SDS-PAGE: Recombinant Human BRD2 His Protein [NBP2-51885]
SDS-Page: Recombinant Human BRD2 Protein [NBP2-51885] - 15% SDS Page (3 ug)Formulation, Preparation and Storage
NBP2-51885
| Formulation | PBS (pH 7.4), 10% glycerol, 1 mM DTT |
| Preservative | No Preservative |
| Concentration | 1 mg/ml |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Background: BRD2
BRD2 and the other BET proteins have been implicated in a variety of diseases and pathologies. The BET proteins are known drivers of cancer through mutation and over-expression (1). Recently, in studies examining the role of Type 2 diabetes and obesity in breast cancer progression, the BET proteins have been shown to be critical regulators of metabolism and metastasis and are co-activators for the transcription of genes that encode pro-inflammatory cytokines in immune cells infiltrating the breast cancer microenvironment (1). Accordingly, knockdown of Brd2 in mice protected the animals from developing Type 2 diabetes and stopped the inflammatory response typically elicited by obesity (4). BRD2 is also highly expressed in the brain and the gene has been shown to play a role in juvenile myoclonic epilepsy, a common form of epilepsy that typically reveals itself during adolescence (5). In addition to the brain, BRD2 is highly expressed in the bone marrow and consequently its kinase activity has been shown to increase upon cellular proliferation and is significantly elevated in the peripheral blood lymphocytes of lymphoma patients (2, 3).
Research has been done to better understand protein interactions with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of the novel coronavirus disease 2019 (COVID-19), as possible targets for drug therapies. It was recently described that that the transmembrane envelope protein (E) of SARS-CoV-2 binds to both BRD2 and BRD4, suggesting that bromodomain inhibitors could be a potential drug target (6). More specifically, the bromodomain inhibitors could be relevant regarding the secondary immune-related consequences that arise from SARS-CoV-2 infection (6). Bromodomain inhibitors are currently the focus of multiple clinical trials as a potential therapeutic in cancer and pulmonary arterial hypertension (6).
References
1. Andrieu, G.P., Shafran, J.S., Deeney, J.T., Bharadwaj, K.R., Rangarajan, A., & Denis, G.V. (2018). BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. J Leukoc Biol. https://doi:10.1002/JLB.5RI0917-380RR
2. BRD2 bromodomain 2 (human), NCBI
3. Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int J Mol Sci. https://doi:10.3390/ijms17111849
4. Wang, F., Deeney, J.T., & Denis, G.V. (2013). Brd2 gene disruption causes "metabolically healthy" obesity: epigenetic and chromatin-based mechanisms that uncouple obesity from type 2 diabetes. Vitam Horm. https://doi:10.1016/B978-0-12-407766-9.00003-1
5. Gilsoul, M., Grisar, T., Delgado-Escueta, A.V., de Nijs, L., & Lakaye, B. (2019). Subtle Brain Developmental Abnormalities in the Pathogenesis of Juvenile Myoclonic Epilepsy. Front Cell Neurosci. https://doi:10.3389/fncel.2019.00433
6. Harrison, C. (2020). Drug researchers pursue new lines of attack against COVID-19. Nat Biotechnol. https://doi.org/10.1038/d41587-020-00013-z
Long Name
Bromodomain Containing 2
Alternate Names
FSRG1, RING3, RNF3
Gene Symbol
BRD2
Additional BRD2 Products
Product Documents for Recombinant Human BRD2 His Protein
Product Specific Notices for Recombinant Human BRD2 His Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...